Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next

Satsuma Pharmaceuticals, Inc. Raises $62 Million in Series B Preferred Stock Financing

Satsuma Pharmaceuticals Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101.

On April 24, 2019, Satsuma announced a $62 million Series-B preferred stock financing led by Wellington Management Company with participation by existing investors and new investors. Financing proceeds will support Phase 3 development of STS101. Satsuma plans to initiate its Phase 3 clinical trial in the third quarter of 2019 (Jul – Sep).

 

For more information, please visit Satsuma’s press release.

1) About migraine

There are currently an estimated 38 million people in the U.S. suffering from migraine headaches, and the market for migraine therapeutics is reported to have reached $16 billion in 2017 in the US alone. A large number of patients are relatively young, within the working age group of 20 and 40 years of age, and there is an existing need for quick relief of potentially-disabling headaches greatly affecting quality of life. DHE is effective for non-responders of triptans, which are currently first-in-line therapies; however, the current liquid nasal spray is slow to absorb, taking at least 30 minutes to take effect, and the product is regarded to be unreliable due to its variability in absorption and difficulty in obtaining clear clinical effectiveness. Satsuma’s STS101 having completed the Phase I clinical trial showing consistently high and rapid absorption with excellent tolerability is expected to meet market needs.